Boston-based CereVasc designed eShunt for treating normal pressure hydrocephalus (NPH). This study evaluates the technology ...
Boston Scientific (NYSE: BSX) shares ticked up slightly before hours today on fourth-quarter results that beat the consensus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback